Intravitreal implants are micro device-like inserts injected into the posterior segment of the eye to treat retinal diseases releasing therapeutic drugs at a set rate over a desired period of time.[1][2] The posterior segment of the eye consists of the sclera, choroid, fovea, vitreous humor, optic nerve, and retina.[3][4]
- ^ Tawfik M, Chen F, Goldberg JL, Sabel BA (December 2022). "Nanomedicine and drug delivery to the retina: current status and implications for gene therapy". Naunyn-Schmiedeberg's Archives of Pharmacology. 395 (12): 1477–1507. doi:10.1007/s00210-022-02287-3. PMC 9630211. PMID 36107200.
- ^ Orlova ER, Gorobets AV, Dorofeev DA, Kirilik EV, Kozlova IV (2022-06-25). "Intravitreal Systems For Targeted Drug Delivery To The Posterior Eye Segment: A Systematic Review". Russian Open Medical Journal. 11 (2): e0213. doi:10.15275/rusomj.2022.0213. S2CID 252724853.
- ^ Bajpai A, Bajpai J, Saini RK, Agrawal P, Tiwari A (2016-12-19). Smart Biomaterial Devices (0 ed.). CRC Press. doi:10.1201/9781315371559. ISBN 978-1-4987-0701-5.
- ^ García-Estrada P, García-Bon MA, López-Naranjo EJ, Basaldúa-Pérez DN, Santos A, Navarro-Partida J (May 2021). "Polymeric Implants for the Treatment of Intraocular Eye Diseases: Trends in Biodegradable and Non-Biodegradable Materials". Pharmaceutics. 13 (5): 701. doi:10.3390/pharmaceutics13050701. PMC 8151640. PMID 34065798.